Isomaltase

QOL Medical, LLC Unveils Its First Sucrose (sugar) Intolerance Disease Awareness Ad Campaign Titled "All Movies End with a Flush" to Tie in with Movie Award Season

Retrieved on: 
Monday, February 18, 2019
Sucrase, Sucrose intolerance, Sugar substitutes, Disaccharides, CSID, Sucrose alpha-glucosidase, Sucrose, Food and drink, Isomaltase, Maltase, Intolerance, Physical objects

VERO BEACH, Fla., Feb. 18, 2019 /PRNewswire/ -- QOL Medical, LLC today unveiled the first Sucrose (sugar) Intolerance ad campaign titled "All Movies End with a Flush."

Key Points: 
  • VERO BEACH, Fla., Feb. 18, 2019 /PRNewswire/ -- QOL Medical, LLC today unveiled the first Sucrose (sugar) Intolerance ad campaign titled "All Movies End with a Flush."
  • This educational, playful radio advertising campaign is timed to coordinate with the movie award season.
  • People with Sucrose Intolerance, medically referred to as Congenital Sucrase-Isomaltase Deficiency (CSID), are unable to properly digest sucrose (table sugar), which is found in foods like ice cream, apples, cake, and corn.
  • QOL Medical is a specialty biopharmaceutical company dedicated to improving clinical outcomes and overall quality of life for patients with rare diseases.

New HealthWell Foundation Fund Offers Financial Assistance to Patients Living with Congenital Sucrase-Isomaltase Deficiency (CSID)

Retrieved on: 
Tuesday, November 27, 2018
CSID, Sucrase, Sucrose intolerance, Sucrose alpha-glucosidase, Maltase, Isomaltase, Lifeline, Copayment, Sacrosidase

GERMANTOWN, Md., Nov. 27, 2018 /PRNewswire/ --The HealthWell Foundation, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has launched a new fund to provide assistance to patients who are living with congenital sucrase-isomaltase deficiency (CSID).

Key Points: 
  • GERMANTOWN, Md., Nov. 27, 2018 /PRNewswire/ --The HealthWell Foundation, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has launched a new fund to provide assistance to patients who are living with congenital sucrase-isomaltase deficiency (CSID).
  • Through the fund, HealthWell will provide up to $10,000 in copayment or premium assistance to eligible patients living with CSID who have annual household incomes up to 500% of the federal poverty level.
  • This fund from HealthWell Foundation will help liftsome of that burden and givefamilies greater access to neededtreatments."
  • "People living with CSID can endure a multitude of uncomfortable, and more often, painful symptoms," commented Krista Zodet, HealthWell Foundation President.

FDA Approves New Manufacturing Facility in Clearwater, Florida for Sacrosidase, Active Ingredient of Sucraid® (sacrosidase) Oral Solution, for the Treatment of Congenital Sucrase-Isomaltase Deficiency

Retrieved on: 
Tuesday, October 2, 2018
Sacrosidase, Sucrase, Sucrose intolerance, CSID, Sucrose alpha-glucosidase, Maltase, Isomaltase

QOL Medical has developed an improved manufacturing process for sacrosidase production, designed and built a wholly owned cGMP-compliant manufacturing facility, and hired an experienced manufacturing and quality team to assure this goal.

Key Points: 
  • QOL Medical has developed an improved manufacturing process for sacrosidase production, designed and built a wholly owned cGMP-compliant manufacturing facility, and hired an experienced manufacturing and quality team to assure this goal.
  • Sucraid (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).
  • Sucraid can help improve the breakdown and absorption of sucrose (table sugar) from the intestine and can help relieve the gastrointestinal symptoms of CSID.
  • Sucraid(sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).

Sucraid® (Sacrosidase) Oral Solution, The Only FDA-Approved Therapy To Treat Congenital Sucrase-Isomaltase Deficiency (CSID), Is Now Available

Retrieved on: 
Tuesday, October 2, 2018
Sucrase, Sacrosidase, Sucrose intolerance, CSID, Hydrolases, Sucrose alpha-glucosidase, Isomaltase, Disaccharides, Maltase, Sucrose, Health, Chemistry

Congenital Sucrase-Isomaltase Deficiency (CSID) usually results in sucrose intolerance and gastrointestinal symptoms as a result of an individual's inability to properly digest sucrose (table sugar).

Key Points: 
  • Congenital Sucrase-Isomaltase Deficiency (CSID) usually results in sucrose intolerance and gastrointestinal symptoms as a result of an individual's inability to properly digest sucrose (table sugar).
  • Patients with a prescription may get a shipment of Sucraid through the standard specialty pharmacy, US Bioservices, at 833-800-0122.
  • Sucraid (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).
  • www.sucraid.net
    Sucraid(sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).